Endurance
Engineered for maximum wear time.
Confidence
Never lose a device.
Freedom
Skin Grip moves with you, never against you.
SHOP BESTSELLERS
Skin Grip Original - Dexcom G6 Patches
Choose your option
Skin Grip MAX Dexcom G6 Patches - 10 Pack
Choose your option
Skin Grip Original - Medtronic Guardian/Enlite Adhesive Patches
Choose your option
Skin Grip Original - Freestyle Libre 2+ & Lingo Adhesive Patches
Choose your option
Skin Grip MAX Dexcom G7 & Stelo Patches - 10 Pack
Choose your option
Skin Grip Original - Dexcom G7 & Stelo Adhesive Patches (With Cutout)
Choose your option
Skin Grip Original - Omnipod Adhesive Patches
Choose your option
Skin Grip Original - Dexcom G7 & Stelo Adhesive Patches
Choose your option
Skin Grip - Tandem Mobi Pocket Patch
Choose your option
Sensors Saved
Trusted By
Say Goodbye To
Sensor Failure Mid-Routine
Adhesion built to last through motion, sweat, and time.
Manufacturer Replacements on Repeat
Designed for reliability — not replacements.
Waiting on New Sensors to Arrive
Every patch extends your wear. Every day counts.
Losing a Reading When Life Gets Close
Holds steady through hugs, heat, and high impact.
Returning to Fingerpricks and Frustration
Performance that stays put. Confidence that stays on.
→ Built to grip. Made to stay.
DIABETES MANAGEMENT
Your go-to hub for tips, tricks, and real talk on living boldly with diabetes
Are We Getting Closer to a Fully “Hands-Off” System?
If you use a CGM or insulin pump, you’ve probably had this thought at some point: “Will there ever be a system that just…handles it for me?” No carb counting, no constant adjustments, no mental math. Just something that works in the background so you can live your life. We’re not fully there yet, but we’re closer than ever. Recent updates from diabetes technology conferences like ATTD show that the industry is steadily moving toward more automated, lower-effort systems. Here’s what that actually means, and how close we are to a true “hands-off” experience. First, Where We Are Today (Quick Reality Check) Current systems like Control-IQ, Omnipod 5, Medtronic SmartGuard, twiist, and iLet already: Adjust insulin automatically Help prevent highs and lows Reduce overnight variability But they still rely on you for: Meal boluses Carb counting (or at least estimating) Managing unexpected situations So while they’re powerful, they’re not fully hands-off. What’s Actually Changing: The Tech Moving Us Forward Here’s where things get interesting and much more specific. 1. Systems That Can Detect Meals (Without You Saying Anything) One of the biggest barriers to full automation has always been meals. At ATTD, multiple research groups and companies presented progress toward systems that can: Detect when you’ve eaten Respond automatically with insulin Correct for missed or underestimated meals Some experimental systems are using AI and pattern recognition to identify meal-related glucose rises in real time without requiring manual carb input. What this means in real life: You forget to bolus…and your system steps in anyway. This alone is one of the biggest steps toward reducing daily decision-fatigue. 2. AI That Predicts What’s About to Happen We’ve had “smart” systems for a while, but what’s new is how predictive they’re becoming. Recent developments include: Algorithms that forecast glucose trends 30+ minutes ahead Systems that adjust insulin before a high or low fully develops AI models that process large amounts of CGM data to recognize patterns faster This is a shift from: reacting to glucose changes to preventing them before they happen 3. Continuous Ketone Monitoring Is Entering the Chat One of the most talked-about developments from ATTD: continuous ketone monitoring (CKM). Companies like Abbott are working on sensors that track both glucose and ketones simultaneously. Why that matters: Ketones provide context that glucose alone can’t They can signal risk earlier (like during illness or insulin disruption) They give automated systems more information to make better decisions This means that future systems won’t just know your number - they’ll understand your metabolic state, which will make automation safer and smarter. 4. Less Carb Counting, More “Good Enough” Input Another clear shift: systems are moving away from requiring precision. Instead of exact carb counts, we’re seeing: Simplified meal announcements (small/medium/large) Systems that correct for estimation errors Algorithms that learn your patterns over time This is especially visible in systems such as iLet, which already reduces the need for detailed setup. 5. Automation That Works for More People (Not Just One Type of User) At ATTD, companies such as Tandem shared data showing automated systems working across: Different insulin needs Different daily routines Broader populations, including type 2 diabetes This matters because: More variability = stronger algorithms Systems are being built to adapt, not assume 6. The Rise of “Co-Pilot” Systems Not every innovation is about full automation. There’s also a growing category of tools that act like a diabetes co-pilot: Apps that analyze your CGM data and suggest actions AI tools that flag patterns you might miss Systems that guide decisions without fully taking over These tools don’t replace you, but they reduce the mental load significantly. So… Are We Close to Fully Hands-Off? Closer than we’ve ever been, but not quite there yet. What’s still challenging: Insulin timing isn’t instant Meals vary too much to perfectly predict every time Activity, stress, and hormones still introduce variability Sensors and delivery systems aren’t perfect But here’s what has changed: We’re no longer just improving devices. We’re building systems that: Learn from you Predict what’s coming Fill in the gaps when you don’t act The Bigger Shift: From Management to Support The most important takeaway isn’t “full automation is coming.” It’s that diabetes tech is moving from something you manage to something that supports you in the background though: Fewer interruptions Less decision fatigue More trust in your system More space to focus on your life Final Thoughts A fully hands-off diabetes system isn’t here yet, but for the first time, we’re seeing real, concrete steps toward it through meal detection, predictive AI, multi-analyte sensors and adaptive algorithms. And while we’re still in the in-between, each update is doing something meaningful: Giving you a little more breathing room so you can live fearlessly.
Read more
Dexcom vs Libre: What’s the Difference Between These CGMs?
If you wear a CGM, chances are you’ve wondered at some point: would the other one work better for me? Maybe your sensor doesn’t always last the full wear time, alerts feel overwhelming, or you’re curious about features you’ve heard other people talk about. Dexcom and FreeStyle Libre 3+ are two of the most widely used CGM systems, and both have their respective pros and cons list. While they ultimately serve the same purpose, the experience of wearing them day to day can feel quite different depending on things like wear time, alerts, integrations, and how they fit into your overall tech setup. In this guide, we’ll break down the practical differences between Dexcom and Libre so you can better understand what each system offers and why some people prefer one over the other. What Dexcom and Libre Have in Common At a basic level, Dexcom and Libre systems do the same thing: they continuously measure glucose levels through a small sensor worn on the body and send those readings to a smartphone or receiver. Both systems: Track glucose trends throughout the day Display readings on a mobile app Allow data sharing with caregivers or family members Reduce the need for frequent fingerstick testing They’re also both small and discreet, roughly the size of stacked coins, and worn on the skin for multiple days at a time. Dexcom CGM Systems Dexcom’s newest CGM is the Dexcom G7, their smallest CGM yet that will replace all G6 sensors after the announced discontinuation in July of 2026. Key features Wear time: 10 days or 15 days depending on the version, plus a 12 hour grace period Warm-up time: 30 minutes Glucose readings: every 5 minutes Alerts: customizable high, low, and predictive alerts Data sharing: Dexcom Follow allows up to 10 followers Integrations: Omnipod 5, Tandem t:slim X2, Tandem Mobi, and Beta Bionics iLet Bionic Pancreas One of Dexcom’s biggest strengths is device integration. Because of the wide variety of choice, Dexcom is often the CGM used in hybrid closed-loop pump systems. FreeStyle Libre CGM Systems Abbott’s FreeStyle Libre family has become one of the most widely used CGM platforms globally. The latest version compatible with closed loop systems is FreeStyle Libre 3+. Key features Wear time: 15 days Warm-up time: 60 minutes Glucose readings: every minute Very small sensor: one of the smallest CGM sensors available Data sharing: LibreLinkUp allows data sharing with up to 20 followers Integrations: Tandem t:slim X2, Beta Bionics iLet Bionic Pancreas, Sequel Med Tech twiist, and a Limited Market Release with Omnipod 5 Libre 3+ sensors is known for its long wear time and small profile, which many users find comfortable and discreet. Key Differences at a Glance Feature Dexcom G7 FreeStyle Libre 3+ Wear time ~10 days or 15 days (+12-hour grace period) ~15 days Warm-up time ~30 minutes ~60 minutes Glucose readings Every 5 minutes Every minute Sensor size 27mm x 23mm x 4.7mm 21mm x 2.9 mm Both systems are highly accurate and widely used, but the experience can feel different depending on what matters most to you. Which CGM Might Fit Your Lifestyle? Different people prioritize different things when choosing diabetes tech. Dexcom G7 may appeal to people who: Use (or want) an automated insulin delivery system Want predictive alerts for low glucose Prefer deeper integration with pumps and apps Libre 3+ may appeal to people who: Prefer longer sensor wear time Want a very small, discreet sensor Like a simple, streamlined CGM experience Ultimately, both systems provide valuable real-time glucose data that can help people understand patterns and make more informed decisions about their diabetes care. The Bottom Line Dexcom and FreeStyle Libre are two of the most advanced CGM platforms available today. Both offer powerful tools for understanding glucose trends, reducing fingersticks, and improving daily awareness. The right option often comes down to lifestyle preferences, device compatibility, and insurance coverage. No matter which system you use, the goal is the same: helping you stay informed, confident, and supported in your daily life with diabetes.
Read more
The Future of Patch Pumps: What’s next for tubeless insulin delivery in 2026 and beyond
Patch pumps have already changed the game for a lot of people with diabetes: no tubing, fewer “where do I clip this?” moments, and a setup that can feel more streamlined for daily life. What’s ahead looks even more interesting - companies are pushing for longer wear, bigger reservoirs, smarter automation, and more flexible ecosystems. Below is a forward-looking roundup of four patch-pump pipelines to watch: Tandem’s tubeless Mobi concept, Beta Bionics’ Mint, Medtronic’s MiniMed Fit, and Insulet’s Omnipod 6. (Heads up: future features and dates can change based on FDA review, clinical testing, and manufacturing timelines). 1) Tandem’s tubeless Mobi: a patch-pump direction for a familiar ecosystem Tandem has been very open that it’s working toward patch-pump options, including a pathway that would transform Mobi into a tubeless patch device via a novel extended-wear infusion site. Tandem also says a next-generation Mobi patch pump is in its pipeline, leveraging technology from its Sigi acquisition. What to watch for Extended wear: Public reporting links Tandem’s SteadiSet (extended-wear infusion set) with the broader push toward longer-wear pump sites. Timeline: Tandem has not pinned a firm consumer launch date for its tubeless Mobi patch device on its public innovations page, but extended-wear components and development milestones are being discussed in 2026-oriented roadmaps. Why it matters: If a Mobi-based patch approach arrives, it could offer a new middle lane between traditional tubed pumps and disposable pods, especially for people who want the flexibility of a patch form factor but prefer a Tandem ecosystem. 2) Beta Bionics Mint: a fresh patch pump with a different philosophy Beta Bionics made waves discussing Mint, its in-development patch pump. Reporting from ADA coverage describes Mint as a 3-day patch pump that holds up to 200 units, with a concept that includes a reusable controller and phone compatibility. What to watch for Wear time & capacity: ~3 days and ~200 units puts it in familiar pod territory Timing: Beta Bionics has indicated a 2027 window for launch, echoed by analyst coverage and earnings call commentary. Why it matters: Competition is good. More patch-pump options means more chances for people to find the setup that fits their preferences, budget, and lifestyle. 3) Medtronic MiniMed Fit: bigger reservoir + longer wear ambitions Medtronic’s MiniMed Fit is one of the most concrete next wave patch pumps on the horizon in terms of reported specs: coverage has repeatedly pointed to ~300 units and ~7-day wear. This is a notable shift as many current pod users are used to ~3 days. What to watch for FDA timing: Medtronic has said it intends to submit Fit to the FDA by fall 2026. Development activity: ClinicalTrials.gov includes a Medtronic study referencing 7-day wear adhesive components for the MiniMed Fit payload, one more public signal that development is actively moving forward. Launch window: Multiple reports suggest market availability likely no earlier than 2027, though timelines can shift. Why it matters: If Fit lands with a true 7-day patch wear experience and a 300-unit reservoir, it could be a major quality-of-life upgrade for people who want fewer change days. 4) Omnipod 6: next-gen evolution of the category leader Insulet has publicly outlined a roadmap that includes Omnipod 6 and has pointed to 2027 as the target launch window. What to watch for Ecosystem upgrades: Insulet has also talked about enhancing the Omnipod 5 ecosystem in 2026 (pending FDA clearance), including broader connectivity and deeper insights, signaling that Omnipod’s software layer and integrations remain a key focus as Omnipod 6 approaches. Wear time & reservoir: Insulet’s core platform messaging still emphasizes “up to three days” of insulin delivery for Omnipod pods. Until Insulet publishes exact Omnipod 6 hardware specs, it’s safest to assume the next-gen system may keep the same form factor. What’s new: Reporting around Investor Day suggests meaningful algorithm and system improvements are part of the Omnipod 6 story. Why it matters: Omnipod has defined the patch pump category for years. Omnipod 6 will likely set the tone for what “baseline expectations” become, especially around automation, connectivity, and user experience. The bottom line: 2026 is about momentum, 2027 looks like a turning point If you zoom out, the direction is clear: longer wear, bigger reservoirs, and smarter systems that fit more naturally into daily life. With big names signaling patch pump roadmaps and multiple products converging on a 2027 window, the future of patch pumps is less a distant concept and more a pipeline that’s actively taking shape. Quick disclaimer Details for in-development devices can change quickly. Always confirm final specs (wear time, reservoir size, CGM compatibility, phone control, waterproofing) on the manufacturer’s site once products are FDA-cleared and commercially released.
Read more
